Aug 24,2023

Long-Term Results of a Digital Hypertension Self-Management Program: Retrospective Cohort Study

Digital health programs that incorporate frequent blood pressure (BP) self-monitoring and support for behavior change offer a scalable solution for hypertension management. The study examined the impact of a digital hypertension self-management and lifestyle change support program provided by Omada Health over 12 months. Data were analyzed from a retrospective observational cohort of commercially insured members (n=1117) that started the Omada for Hypertension program between January 1, 2019, and September 30, 2021. At 12 months, all members (including members with controlled and uncontrolled BP at baseline) and those with uncontrolled systolic BP at baseline experienced significant mean reductions in SBP (mean -4.8 mm Hg). Members with uncontrolled systolic BP at baseline also had significant reductions in diastolic blood pressure (-4.7 mm Hg), weight (-6.5 lbs), and BMI (-1.1 kg/m2). Those with controlled Systolic BP at baseline maintained within BP goal range. Additionally, 48% (418/860) of members with uncontrolled BP at baseline experienced enough change in BP to improve their BP category.

CLINICAL STUDY

#virtual care

#cbt

View Analyst & Ambassador Comments
Go to original news
Sep 27,2023 TOP STORY

Dario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs

DarioHealth announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the impact of coaching and breathing exercises as part of the Dario digital behavioral health program alongside coaching and breathing exercises for members living with depression or anxiety. The study ''Specifying the Efficacy of Digital Therapeutic Tools for Depression and Anxiety: Retrospective, 2-Cohort, Real-World Analysis'' analyzed the data of participants in two cohorts engaged in Dario's digital self-guided programs who started at a moderate or high level of depression or anxiety. These study participants engaged in Dario's digital programs alongside the use of a coach or digitally-delivered breathing exercises over the course of 16 weeks to understand the impact of these support mechanisms. The analysis revealed a significant decrease in depression and anxiety symptoms during the first six weeks which was maintained throughout the rest of the 16 weeks program. 63% of members using Dario to manage depression experienced an overall improvement in symptoms, and the use of coaching support significantly moderated symptoms in the first six weeks.

CLINICAL STUDY

#cbt

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 02,2019

metaMe Health Announces First Subject Enrolled in Pivotal Study of a Digital Therapeutic for Treatment of IBS

metaMe Health, Inc., a Chicago-based prescription digital therapeutics company committed to the treatment of gastrointestinal (GI) conditions such as Irritable Bowel Syndrome (IBS), today announced that the first subject has enrolled in a pivotal study to evaluate the efficacy and safety of an all-digital, self-administered behavioral therapy for the treatment of adult subjects with symptomatic IBS.  This trial is a randomized, controlled, parallel-group study that will enroll subjects from across the United States. metaMe expects to enroll approximately 380 patients, aged 18 years and older, to the study, in partnership with the digital clinicial trials company Curebase. Initial results are expected by the second half of 2020.

CLINICAL STUDY

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023 TOP STORY

Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics

Mahana Therapeutics announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit, Precision Health, focused on delivering new digitally enabled precision health products to market. Bayer is prioritizing development of products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms. David Evendon-Challis, Head of R&D and Chief Scientific Officer for the Consumer Health division of Bayer added, “Digital therapeutics are a perfect addition to our portfolio of care and tap into new tech-savvy consumers looking for drug-free treatments as well as help eliminate gaps in care provision. We’re excited to partner with Mahana Therapeutics and enter the field of digital therapeutics in consumer health.”

COLLABORATION PARTNERSHIP

#institution

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 18,2023

Welt, Aimmed face delays in launching Korea's first approved DTx devices

Korea approved two digital therapeutics (DTx) devices this year but there has been no news about the market launch since the Ministry of Food and Drug Safety (MFDS) granted the approval for these innovative devices from Aimmed and Welt in February and April this year respectively. As the developers of the first approved DTx devices in Korea, both Welt and Aimmed are exploring uncharted territory. However, even after receiving approval, both companies have to prepare for the pilot project to accumulate real-world evidence of the DTx device, as required by the National Evidence-based Healthcare Collaborating Agency (NECA). Welt CEO Sean Kang expressed his frustration with the slow launch saying that it was being delayed as they were required to jump through several hoops to undergo a pilot project.

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 06,2017

Your Facebook Messenger AI therapist will see you now

The interview discusses Woebot, an AI-based virtual therapist available on Facebook Messenger. Dr. Alison Darcy, the creator of Woebot, explains that its conversational style is designed to make users feel comfortable discussing their mental health. Woebot engages users in conversation to address common fears around therapy and offers support for various mental health concerns. It is built to meet users where they are and provides resources for crisis situations. Clinical research showed that Woebot significantly reduced symptoms of depression and anxiety over a two-week period. Woebot offers tiered pricing for its services and employs a combination of decision trees, keyword triggers, Natural Language Processing (NLP), and machine learning to provide effective interactions.

#chatbot

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 05,2023

Mental Health App Woebot Passes ORCHA's Rigorous New Digital Health Assessment Framework

Woebot, a mental health app from Woebot Health that provides personal and immediate support to people who are experiencing symptoms of anxiety and depression, has passed the rigorous new Digital Health Assessment Framework (DHAF) that aims to enhance health application standards in the United States. The open framework includes components to assess privacy and security, clinical assurance and safety, and usability, and was crafted to support U.S.-specific guidelines, regulations and best practices for digital health technologies.

PRODUCT

#chatbot

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 10,2023

Supporting clinicians with effective digital treatments

Big Health partners with the American Psychological Association to increase awareness of the value and impact of digital treatments in clinical care delivery. Last week, Big Health announced an exclusive partnership with the American Psychological Association (APA) to advance education on the benefits of digital treatments for common mental health conditions like insomnia, anxiety, and depression. Jenna Carl, PhD, practicing psychologist and Chief Medical Officer at Big Health reflects on the imporatance of this exclusive partnership with APA in an interview.

COLLABORATION PARTNERSHIP

#institution

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Oct 06,2020

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

The objective of the study was to test the preliminary effectiveness of Quit Genius, a novel digital therapeutic intervention for smoking cessation. A 2-arm, single-blinded, parallel-group randomized controlled trial design was used. A total of 556 adult smokers (aged 18 years or older) smoking at least 5 cigarettes a day for the past year were recruited. Of these, 530 were included for the final analysis. Participants were randomized to one of 2 interventions. Treatment consisted of a digital therapeutic intervention for smoking cessation consisting of a smartphone app delivering cognitive behavioral therapy content, one-to-one coaching, craving tools, and tracking capabilities. The control intervention was very brief advice along the Ask, Advise, Act model.All participants were offered nicotine replacement therapy for 3 months. Participants in a random half of each arm were pseudorandomly assigned a carbon monoxide device for biochemical verification. At 4 weeks post quit date, 44.5% of participants in the treatment arm had not smoked in the preceding 7 days compared with 28.7% in the control group.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 18,2018

Evaluation of Two Mobile Health Apps in the Context of Smoking Cessation: Qualitative Study of Cognitive Behavioral Therapy (CBT) Versus Non-CBT-Based Digital Solutions

Although the evidence base for computerized CBT in mental health is strong, there is limited literature on its use in smoking cessation. This, combined with the cost-effectiveness of mHealth interventions, advocates a need for research into the effectiveness of CBT-based smoking cessation apps. The objective of this study was, first, to explore participants’ perceptions of 2 mHealth apps, a CBT-based app, Quit Genius, and a non-CBT-based app, NHS Smokefree, over a variety of themes. Second, the study aimed to investigate the perceptions and health behavior of users of each app with respect to smoking cessation. A qualitative short-term longitudinal study was conducted, using a sample of 29 smokers allocated to one of the 2 apps, Quit Genius or Smokefree. Each user underwent 2 one-to-one semistructured interviews, 1 week apart. Quit Genius users reported increased motivation to quit smoking, as well as greater willingness to continue using their allocated app after 1 week.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CBT